The price of cancer drugs is too high, an increasingly significant issue in U.S. health care expenditures. In this op-ed for the Washington Post, Hagop Kantarjian, scholar in health policy, explains how to reduce the price of cancer drugs.
The price of cancer drugs is too high, an increasingly significant issue in U.S. health care expenditures. In this op-ed for the Washington Post, Hagop Kantarjian, scholar in health policy, explains how to reduce the price of cancer drugs.